Investors

annual reportS

RAD Annual Report June 2022

September 2022

RAD ESG Report 2022

September 2022

shareholder newsletter

Radiopharm Newsletter December 2022

December 2022

Radiopharm Newsletter July 2022

July 2022

Radiopharm Newsletter March 2022 - Meet our CEO in Australia

March 2022

Radiopharm Theranostics Newsletter Dec 2021

December 2021

ANalyst coverage

Bell Potter Initiation of Coverage - Going After Cancer

March 2023

Diamond Equity Research update Valuation at 70 cents per share

February 2023

Diamond Equity Research update Valuation to 70 cents per share

December 2022

Diamond Equity Research increases Valuation to 88 cents per share

August 2022

Bioshares RAD Update 17 June 2022

June 2022

Bioshares - RAD Update 3 June 2022

June 2022

Diamond Equity Research - Valuation at 87 cents per share - Another meaningful addition to the Pipeline

June 2022

Diamond Equity Research increases valuation to 87 cents per share - Transformative acquisition and progress in clinical trials to drive value

April 2022

Diamond Equity Research Report Feb 2022

February 2022

Diamond Equity Research initiates coverage with valuation 84 cents per share Jan 2022

January 2022

Radiopharm (ASX:RAD) - Independent Investment Research initiates coverage with valuation of 86 cents per share

December 2021

corporate governance

Radiopharm Theranostics Prospectus and Supplementary Disclaimers

Radiopharm Theranostics Prospectus

Radiopharm Theranostics Supplementary Prospectus

Corporate Governance

corporate policies

Privacy Policy

Sign up to our mailing list.

Receive all the latest news from Radiopharm Theranostics.